time) on the business day following the date of the relevant transaction. This requirement will continue until the date on which the Scheme becomes effective or on which the 'offer period' otherwise ends. If two or more persons co-operate on the basis of any agreement, either express or tacit, either oral or written, to acquire an 'interest' in 'relevant securities' of Warner Chilcott
or Actavis, they will be deemed to be a single person for the purpose of Rule 8.3 of the Irish Takeover Rules.
Under the provisions of Rule 8.1 of the Irish Takeover Rules, all 'dealings' in 'relevant securities' of Warner Chilcott by Actavis or 'relevant securities' of Actavis by Warner Chilcott, or by any of their respective 'associates' must also be disclosed by no later than 12 noon (Dublin time) on the 'business' day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose 'relevant securities' 'dealings' should be disclosed, can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.
'Interests in securities' arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an 'interest' by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Irish Takeover Rules, which can also be found on the Irish Takeover Panel's website. If you are in any doubt as to whether or not you are required to disclose a dealing under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover PPage: 1 2 3 4 5 6 7 Related medicine technology :1
. U.S. Supreme Court Reverses U.S. Court of Appeals Decision in FTC v. Actavis2
. Actavis and Medicines360 Announce Partnership to Advance Womens Access to Affordable IUDs3
. New Breakthroughs Allow Companies to Expand their Reach - Research Report on Perrigo, Auxilium, Actavis, Mylan, and Salix4
. Actavis, Inc. to Present at the Goldman Sachs 34th Annual Global Healthcare Conference 20135
. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy6
. Actavis NDA for Progestin-Only Patch Accepted for Filing by FDA7
. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference8
. Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc9
. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference10
. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion11
. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel